DRAXIS Announces Application for Normal Course Issuer Bid
11 Gennaio 2008 - 2:00PM
PR Newswire (US)
MONTREAL, Jan. 11 /PRNewswire-FirstCall/ -- DRAXIS Health Inc,
(TSX: DAX) (NASDAQ:DRAX) has applied to the Toronto Stock Exchange
(TSX) to make a Normal Course Issuer Bid (NCIB), subject to TSX
approval, to buy back its common shares through the facilities of
the TSX. The maximum number of common shares which may be purchased
for cancellation pursuant to the NCIB is such number of common
shares which represents 10% of the common shares in the public
float on the date the TSX approves the NCIB. Based on the
40,720,539 common shares in the public float as at December 31,
2007, that maximum number would be 4,072,054. The actual number of
common shares purchased, if any, and the timing of such purchases
will be determined by DRAXIS considering market conditions, stock
prices, its cash position, and other factors. The Board of
Directors of DRAXIS believes that the underlying value of DRAXIS is
not reflected in the current market price of its common shares, and
may not be so reflected at certain times during the course of the
NCIB, and has thus concluded that the repurchase of common shares
pursuant to the proposed NCIB presently constitutes an appropriate
use of financial resources and would be in the best interest of
shareholders. Purchases under the NCIB are expected to be permitted
to commence on or about January 21, 2008 and will terminate on
January 20, 2009 or the date upon which the maximum number of
common shares have been purchased by DRAXIS pursuant to the NCIB.
There cannot be any assurances as to how many shares, if any, will
ultimately be acquired by DRAXIS under the NCIB, and DRAXIS intends
that any shares acquired pursuant to the NCIB will be cancelled.
Any purchases made pursuant to the NCIB will be made in accordance
with the rules of the TSX and will be made at the market price of
the common shares at the time of the acquisition. DRAXIS will make
no purchases of common shares other than open market purchases
which may be made during the period that the NCIB is outstanding.
About DRAXIS Health Inc. DRAXIS Health, through its wholly owned
operating subsidiary, DRAXIS Specialty Pharmaceuticals Inc.,
provides products in three categories: sterile products,
non-sterile products and radiopharmaceuticals. Sterile products
include liquid and freeze-dried (lyophilized) injectables plus
sterile ointments and creams. Non-sterile products are produced as
solid oral and semi-solid dosage forms. Radiopharmaceuticals are
used for both therapeutic and diagnostic molecular imaging
applications. Pharmaceutical contract manufacturing services are
provided through the DRAXIS Pharma division and
radiopharmaceuticals are developed, produced, and sold through the
DRAXIMAGE division. DRAXIS employs approximately 500 staff in its
Montreal facility. For additional information please visit
http://www.draxis.com/ Caution Concerning Forward-Looking
Statements This news release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended (the "Securities Act") and Section 21E of the Securities
Exchange Act of 1934, as amended (the "Exchange Act") and as
contemplated under other applicable securities legislation. These
statements can be identified by the use of forward-looking
terminology such as "may," "will," "expect," "anticipate,"
"estimate," "continue," "plan," "intend," "believe" or other
similar words. These statements discuss future expectations
concerning results of operations or financial condition or provide
other forward-looking information. Our actual results, performance
or achievements could be significantly different from the results
expressed in, or implied by, those forward-looking statements. You
should not place undue reliance on any forward-looking statement,
which speaks only as of the date made. These statements are not
guarantees of future performance. By their nature, forward-looking
statements involve numerous assumptions, known and unknown risks,
uncertainties and other factors that may cause the actual results
or performance of the Company to be materially different from such
statements or from any future results or performance implied
thereby. Factors that could cause the Company's results or
performance to differ materially from a conclusion, forecast or
projection in the forward-looking statements include, but are not
limited to: - the achievement of desired clinical trial results
related to the Company's pipeline products; - timely regulatory
approval of the Company's products; - the ability to comply with
regulatory requirements applicable to the manufacture and marketing
of the Company's products; - the Company's ability to obtain and
enforce effective patents; - the non-infringement of third party
patents or proprietary rights by the Company and its products; -
factors beyond our control that could cause interruptions in our
operations in our single manufacturing facility (including, without
limitation, material equipment breakdowns); - reimbursement
policies related to health care; - the establishment and
maintenance of strategic collaborative and commercial
relationships; - the Company's dependence on a small number of key
customers; - the disclosure of confidential information by our
collaborators, employees or consultants; - the preservation of
healthy working relationships with the Company's union and
employees; - the Company's ability to grow the business; - the
fluctuation of our financial results and exchange and interest rate
fluctuations; - the adaptation to changing technologies; - the loss
of key personnel; - the avoidance of product liability claims; -
the loss incurred if current lawsuits against us succeed; - the
volatility of the price of our common shares; - market acceptance
of the Company's products; - factors described under "Outlook" in
the Company's MD&A for the most recent quarter; and - the risks
described in "Item 3. Key Information - Risk Factors" in the Annual
Report Form 20-F filed by the Company with the United States
Securities and Exchange Commission and which is also filed as the
Company's Annual Information Form with Canadian securities
regulators. For additional information with respect to certain of
these and other factors, and relating to the Company generally,
reference is made to the Company's most recent filings with the
United States Securities and Exchange Commission (available on
EDGAR at http://www.sec.gov/) and the filings made by the Company
with Canadian securities regulators (available on SEDAR at
http://www.sedar.com/). The forward-looking statements contained in
this document represent the Company's expectations as at January
10, 2008. Unless otherwise required by applicable securities laws,
the Company disclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise. DATASOURCE: DRAXIS Health
Inc. CONTACT: DRAXIS Health Inc.: Jerry Ormiston, Executive
Director, Investor Relations, Tel: (877) 441-1984
Copyright
Grafico Azioni Draxis Health (MM) (NASDAQ:DRAX)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Draxis Health (MM) (NASDAQ:DRAX)
Storico
Da Giu 2023 a Giu 2024